Moa

Remepy Launches with $15 Million in Funding To Bring First Hybrid Drug To Market

Retrieved on: 
星期三, 五月 1, 2024
Research, Infectious Diseases, Clinical Trials, Health Technology, Philanthropy, General Health, Pharmaceutical, Health, Science, Oncology, Brain, MCI, Cancer, IP, Blood, Magnetic resonance, Immunotherapy, Pharmacotherapy, Speech, Digital, Therapy, Moa, Patient, Physician, Movement, Biomarker, Immune system, Mechanism, Sensory deprivation, Medical imaging

Remepy, a pioneer in “hybrid drugs,” today announced that it has successfully closed a $10M seed investment round, which together with earlier funding totals $15M.

Key Points: 
  • Remepy, a pioneer in “hybrid drugs,” today announced that it has successfully closed a $10M seed investment round, which together with earlier funding totals $15M.
  • The digital molecules are designed for hybrid drug experiences.
  • Remepy’s innovative approach creates a new market for hybrid medications, and a whole new world of data and IP assets for pharmaceutical companies.
  • Remepy is pioneering Hybrid Drugs: traditional drugs combined with digital therapeutics that are personalized and enhance the effect of pharmaceutical treatments.

HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML)

Retrieved on: 
星期二, 四月 23, 2024
CDK6, Probability, Pharmacokinetics, Trial of the century, AML, Scientific Reports, Moa, CSF1R, FLT3, Pharmacology, SAN, Nature Portfolio, Pharmaceutical industry

Narazaciclib (HX301 or ON123300) is a clinical stage small molecule investigational new drug jointly developed by HanxBio and its business partner OncoNova Therapeutics, Inc. (now Traws Pharma, Inc.).

Key Points: 
  • Narazaciclib (HX301 or ON123300) is a clinical stage small molecule investigational new drug jointly developed by HanxBio and its business partner OncoNova Therapeutics, Inc. (now Traws Pharma, Inc.).
  • In this peer-reviewed article, the researchers from HanxBio described comprehensive pharmacology characterization of HX301 using a series of preclinical experimental AML models, including in vitro cell lines, and in vivo cell line-derived xenografts (CDXs) and patient-derived xenografts (PDXs).
  • This report also studied the pharmacodynamics and pharmacokinetics of HX301, including the relationship between drug exposure and efficacy, which can be used to assist clinical dosage selection.
  • The results of this study will guide our clinical development strategies for HX301 for the treatment of AML."

Moa to develop next-gen bioherbicides in new 10-year commercial partnership with Croda

Retrieved on: 
星期三, 三月 13, 2024
Farmer, Biotechnology, Learning, Agriculture, Partnership, University, Research, Nature, Moa, Herbicide

The partnership aims to develop next-generation bioherbicides for land-based farms by combining Croda’s extensive research into the marine microbiome – developed by its Nautilus Biosciences subsidiary in Canada – with Moa’s own unique herbicide discovery engine.

Key Points: 
  • The partnership aims to develop next-generation bioherbicides for land-based farms by combining Croda’s extensive research into the marine microbiome – developed by its Nautilus Biosciences subsidiary in Canada – with Moa’s own unique herbicide discovery engine.
  • Croda’s advanced manufacturing capabilities will help bring to the field new products identified from the collaboration.
  • Moa already has a diverse pipeline of new herbicides – both biological and synthetic – some of which it is developing on its own, and some with industry partners.
  • Together we can unlock potential commercial solutions as we work towards a mutually beneficial relationship between Croda and nature for a thriving planet and society.

Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis

Retrieved on: 
星期一, 三月 11, 2024
Eosinophil, Fever, Week, Headache, OX40L, Conjunctivitis, Scleroderma, Teaching hospital, Atopic dermatitis, Upper respiratory tract infection, Part, Asthma, TARC, Conference, AAD, Safety, Biomarker, Part Two, Hidradenitis suppurativa, IGA, Patient, Inflammation, Chills, Moa, Serum, American Academy, Pharmaceutical industry

The safety profile was consistent with Part 1 of the study with amlitelimab being well-tolerated and no new safety concerns identified.

Key Points: 
  • The safety profile was consistent with Part 1 of the study with amlitelimab being well-tolerated and no new safety concerns identified.
  • Overall rates of treatment-emergent adverse events (TEAEs) were 69.8% for continued amlitelimab treatment, 71.9% for the amlitelimab withdrawal-arm and 66.7% for placebo.
  • TEAEs more commonly observed included headache (11.6% amlitelimab continuation, 3.9% amlitelimab withdrawal, 6.7% placebo), upper respiratory tract infection (9.3% amlitelimab continuation, 5.5% amlitelimab withdrawal, 20% placebo).
  • Amlitelimab is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.

AgPlenus Achieves Milestone in Collaboration with Corteva to Develop Novel Herbicides

Retrieved on: 
星期三, 三月 6, 2024
Weed control, Corteva, Chemistry, Farmer, Mode of action, Moa, Crop protection, Herbicide, Agriculture, Mortality

The milestone marks the successful identification of a new family of molecules exhibiting herbicidal effect through a novel Mode of Action (MoA), APCO-12, discovered by AgPlenus.

Key Points: 
  • The milestone marks the successful identification of a new family of molecules exhibiting herbicidal effect through a novel Mode of Action (MoA), APCO-12, discovered by AgPlenus.
  • Most commercially available herbicides are based on small molecules that inhibit target proteins (MoAs) in weeds, leading to weed mortality.
  • Today, AgPlenus announced that, together with Corteva, they have identified a new potential class of herbicidal molecules through a novel MoA APCO-12.
  • Dr. Dan Gelvan, CEO of AgPlenus, said "we are excited about the milestone achieved in our collaboration with Corteva Agriscience, which reflects the synergy established between the teams.

Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights

Retrieved on: 
星期五, 二月 16, 2024
Caregiver, Education, Physician, Neurology, Biomarker, DMTS, Patient, Practitioner, MOA, Disease, Diagnosis, Moa, Tremor, Research, Pharmaceutical industry

Spherix Global Insights’ Market Dynamix™: Parkinson’s Disease (US) study surveyed US neurologists (n=101) to analyze patient presentation patterns, current treatment paradigms, and need for potential DMTs.

Key Points: 
  • Spherix Global Insights’ Market Dynamix™: Parkinson’s Disease (US) study surveyed US neurologists (n=101) to analyze patient presentation patterns, current treatment paradigms, and need for potential DMTs.
  • Further, critical to the success of future gene therapies and DMTs is the identification of biomarkers associated with PD.
  • This underscores the importance of manufacturers engaging with healthcare professionals to provide insights into emerging therapies and MOAs.
  • Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.

CatenaBio Selected to Present on its Next Generation Platform and Multi Payload Conjugates (MPC®) at the Berkeley Bio Startup Showcase @JPM

Retrieved on: 
星期四, 一月 4, 2024
Research, Genetics, Clinical Trials, Health Technology, Biotechnology, Health, Pharmaceutical, Science, Oncology, Conference, Moa, Multi, San Francisco Bay Area, UC, Doctor of Philosophy, Serum, Catena, University, University of California, Berkeley, Abstract, Dicarboxylic acid, Safety, Therapy, ADC

CatenaBio was founded to develop novel therapeutics by forming never-before-possible structures enabled by its proprietary technology, which can modify and combine proteins with unmatched selectivity.

Key Points: 
  • CatenaBio was founded to develop novel therapeutics by forming never-before-possible structures enabled by its proprietary technology, which can modify and combine proteins with unmatched selectivity.
  • The company’s CysTyr® platform utilizes the novel Catenase® enzyme, engineered to selectively attach tyrosine residues with cysteine residues to form the proprietary C-Y Bond®.
  • Catena is developing a first-in-class pipeline of Multi Payload Conjugates (MPC®) to deliver targeted combination therapies designed to overcome tumor resistance and potentially lead to superior efficacy and toxicity profiles.
  • Tested in vitro across multiple HER2+ cell lines, the MPCs® demonstrated improved efficacy compared to the current standard of care, DS8201a (T-DXd).

Moa Technology hires for further growth with expansion of its leadership team – announcing appointment of CFO and US-based CBO to support advancement of next-generation herbicides

Retrieved on: 
星期一, 十一月 20, 2023
Triangle Park (Quezon City), Corporation, Silence Therapeutics, Research, Research Triangle Park, Bachelor of Science, Business development, Therapy, CFO, Flagship Pioneering, University College Dublin, Biology, Bayer, GSK, Farmer, Health, Mergers and acquisitions, MBA, University, Growth, Doctor of Philosophy, Bioherbicide, Control, Newcastle University, Herbicide, CBO, Management, Pharmaceutical industry, Telescopic sight, Agriculture, Biochemistry, Syngenta, Apostolos, Moa

He has extensive experience of helping biotech companies raise funding, both through equity funding and industry collaborations.

Key Points: 
  • He has extensive experience of helping biotech companies raise funding, both through equity funding and industry collaborations.
  • His appointment also reflects Moa’s use of cutting-edge biotechnology processes to identify, understand and develop next-generation herbicides with game-changing speed and accuracy.
  • Without effective herbicides, farmers can lose up to 40% of their crop yield as a result of weed growth.
  • Dr. Virginia Corless, Chief Executive Officer of Moa Technology, says:
    “Moa is tackling a major crisis that threatens farmers’ livelihoods and global food security.

Safety Shot’s Highly Anticipated Wellness Beverage that Reduces Blood Alcohol Content Set to Launch First Week of December 2023 at www.DrinkSafetyShot.com & www.Amazon.com

Retrieved on: 
星期一, 十月 30, 2023
Spindrift, Albertsons, Walmart, Anheuser-Busch, Target, Safety, CNS, BAC, Kroger, Moa, Marketing, Restaurant, Mineral, Blood, Keurig Dr Pepper, Blood alcohol content, Central nervous system, Costco

The Company plans to launch business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars in the first quarter of 2024.

Key Points: 
  • The Company plans to launch business-to-business sales of Safety Shot to distributors, retailers, restaurants, and bars in the first quarter of 2024.
  • Safety Shot’s launch is boosted by the Company’s engagement of Advantage Solutions, which deploys its expansive sales, marketing, and technology solutions to ramp and grow sales.
  • A recent study of the nutraceutical functional beverage version of Safety Shot, set to launch in December, reduced blood alcohol content (BAC) within 30 minutes.
  • A more concentrated, prescription version of the Safety Shot formula is being developed as a detox product for alcohol poisoning.

Another Medicine to Stop Migraine in its Tracks – Zavzpret™ is Now Available, but Where will Neurologists use it?

Retrieved on: 
星期四, 八月 17, 2023
Migraine, Roa, Moa, COVID-19, Perception, Prescription, CGRP, Launch, Neurology, DHE, Projection, RealTime, Dihydroergotamine, Patient, Physician, Mall of America, FDA, Impeller, Nasal spray, First Ever, Pfizer, Pharmaceutical industry, Ubrogepant

Now with the July commercial availability of Zavzpret, Spherix has begun tracking its launch in the Launch Dynamix™: Zavzpret for Acute Treatment of Migraine study.

Key Points: 
  • Now with the July commercial availability of Zavzpret, Spherix has begun tracking its launch in the Launch Dynamix™: Zavzpret for Acute Treatment of Migraine study.
  • As of June, over three-quarters of physicians planned to prescribe Zavzpret to their migraine patients within the first six months of availability.
  • One way to tease apart the relative advantages and disadvantages of new migraine therapies is to utilize Spherix’s Launch Dynamix™: Zavzpret series.
  • Spherix will be tracking the awareness and perception of these investigational, pipeline therapies in its separate service, RealTime Dynamix™.